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Summary Regional chemotherapy allows further exploitation of the steep dose response curve of most
chemotherapeutic agents, while systemic toxicity remains tolerable. We investigated the difference in maximally
tolerated dose, pharmacokinetics and antitumour effect comparing administration of melphalan as a bolus in
isolated liver perfusion (ILP) or via hepatic artery infusion (HAI). For these in vivo studies an experimental
model for liver metastases in male WAG/Ola rats is obtained by subcapsular inoculation of CC531 rat colon
carcinoma cells. In this system, ILP allowed administration of a two times higher dose than HAI (12 mg kg-'
vs 6 mg kg-'). In both treatment modalities systemic toxicity (leukopenia) was dose limiting. No hepatic
toxicity was observed. Bolus administration of the maximally tolerated doses ofmelphalan in HAI (6 mg kg-')
and ILP (12mg kg-') resulted in four times higher concentrations in both liver and tumour tissue of the ILP
treated rats. However, the ratio of mean drug concentration in liver vs tumour tissue appeared to be 1.5 times
that found for HAI. In the range of the in tumour tissue measured melphalan concentrations the CC531 cells
showed a steep dose response relationship in vitro. Whereas HAI resulted in significant tumour growth delay,
complete remissions were observed in 90% of the rats treated with ILP.
This study shows that with 12mg kg-' melphalan in ILP highly effective drug concentrations are achieved
in CC531 tumour tissue; although the melphalan concentration in liver tissue shows an even higher increase
than in tumour tissue, hepatic toxicity is negligible in this dose range. This suggests that it might be
worthwhile to apply melphalan in a clinical phase I/II study of ILP.
Colorectal cancer is the second most common form of malig-
nancy encountered in the Western World (Silverberg &
Lubera, 1988). Following initial curative resection of the
primary colorectal tumour, 35% to 60% of the patients die
with liver metastases (Kemeny & Golbey, 1980; August et
al., 1984).
The presence of liver metastases is a major prognostic
factor, survival being largely determined by the extent of
hepatic disease at presentation (Wood et al., 1976; Cady,
1983; Kemeny et al., 1989). Resection of the hepatic meta-
stases is the only hope for prolonged survival, increasing the
5 year survival rates from 3% to about 30% (Wagner et al.,
1984; Hughes et al., 1986). Because colorectal carcinoma is
highly resistant to chemotherapy, at present little can be
offered to patients with irresectable metastases. However,
many anticancer agents show steep dose-response relation-
ships and this has encouraged the development of treatment
modalities allowing exposure to higher local drug concentra-
tions. Based upon the concept that liver metastases derive
their blood flow mainly from the hepatic artery, continuous
hepatic artery infusion (HAI) with fluorodeoxyuridine has
been widely used, resulting in significantly higher response
rates, but not in prolonged survival (Kemeny et al., 1987;
Chang et al., 1987; Hohn et al., 1989; Martin et al., 1990).
Various research groups have experimented with an isolat-
ed liver perfusion (ILP) technique (Aigner et al., 1982; Aigner
et al., 1983; Skibba, 1983, van de Velde et al., 1986; Radnell
et al., 1990). Although ILP with 5-fluorouracil (FUra) and
mitomycin C (MMC) has recently been applied in patients by
Aigner et al. (1988), data on the effectiveness of this app-
roach are not yet available. In experimental studies in rats,
the effectiveness of ILP has been reported for FUra (Radnell
et al., 1990; Marinelli et al., 1990b) and MMC (Marinelli et
al., 1991). Only with MMC complete remissions and a signi-
ficantly prolonged survival has been reported (Marinelli et
al., 1991). In rats, hepatotoxic side effects of MMC was dose
limiting (Marinelli et al., 1990a). In six out of seven evaluable
patients treated with 30 mg m-2 of MMC in ILP an objective
response was seen (> 50% tumour volume reduction on
CT). Unfortunately, as in rats hepatotoxicity did not allow
further dose escalation (manuscript in preparation).
The present study focussed on the application of melpha-
lan in isolated liver perfusion in the rat. Melphalan was
chosen because (1) in contrast with MMC (Lazarus et al.,
1982) melphalan resulted in only mild, asymptomatic, and
transient elevation of liver function tests when patients were
treated with five times higher drug doses than the recom-
mended single bolus doses i.v. and autologous bone marrow
transplantation (Lazarus et al., 1983; Leff et al., 1986), (2) a
small increase in the intracellular concentration ofmelphalan
may translate into dramatic therapeutic improvement (Vis-
tica, 1983), (3) an impressively high overall response rate of
47% to high dose melphalan (180 mgm-2) was noted in
patients with colon cancer (Leff et al., 1986) and (4) recently
four patients have been treated with 0.5 mgkg-' melphalan
in isolated liver perfusion resulting in exposure of liver and
tumours to ten times higher drug concentrations than after
administration of the same dose i.v. (Hafstrom et al., 1990)
without liver toxicity.
In rats first the dose limiting toxicity and maximally toler-
ated dose in ILP and HAI were determined. Subsequently,
these treatment modalities were compared with respect to the
maximally achievable concentration of melphalan in tumour
tissue and the antitumour effect.
The differences in the results of this study with melphalan
and a previously published study with MMC (Marinelli et
al., 1990a) will be discussed.
Materials and methods
Rats
Wistar derived, inbred male WAG/Ola rats (Harlan/CPB,
Zeist, The Netherlands) were used. At the time of tumour
inoculation, the weight of the rats was 260 to 360 g in the
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toxicity and pharmacokinetic study and 230 to 280 g in the
antitumour effect study. The rats were fed laboratory chow
and water ad libitum.
Surgicalprocedures
All operative procedures were carried out under clean but
not sterile conditions, using a microscope (Applied Fiber-
optics, Southbridge, MA, USA) at 20 times magnification.
Anaesthesia was induced and maintained by ether.
(1) Isolated liver perfusion with two inflow limbs This tech-
nique has been previously described in detail (de Brauw et
al., 1988; Marinelli et al., 1990a). In short, after performing a
midline abdominal incision cannulas were inserted into the
gastroduodenal artery and the pyloric vein with their tips in
the hepatic artery and portal vein respectively. For the out-
flow, one cannula was inserted into the caval vein. To isolate
the liver, all normal in- and outflow routes were clamped, the
caval vein between liver and diaphragm and between right
renal vein and the cannula, the aorta proximal of the coeliac
axis, the common hepatic artery and portal vein just proxi-
mal of the cannulas. The outflow of the liver was collected in
a reservoir/oxygenator with heat exchanger and then reinfus-
ed simultaneously into the portal vein (20 ml min-') and
hepatic artery (4.5 ml minm-). The perfusate consisted of
blood, Haemaccel (Hoechst, Amsterdam, The Netherlands),
heparin (50 U) and bicarbonate to adjust pH to 7.3. The
temperature of the perfusate was regulated at 38C and the
oxygen saturation was 99%. Melphalan was injected as a
bolus in the reservoir and perfusion was carried out for
25 min. At the end of the perfusion a washout was performed
with saline. The total operation time was 2-2.5 h.
(2) Hepatic artery infusion A cannula was inserted into the
gastroduodenal artery with the tip in the hepatic artery.
During a 2 min bolus melphalan infusion, the common hep-
atic artery was clamped to prevent retrograde flow into the
coeliac axis and the aorta. The total operation time was
20-30 min.
Tumour model
CC531 is a dimethylhydrazine induced adenocarcinoma of
the colon, syngeneic for WAG rats (Marquet et al., 1984).
An established cell line was maintained in culture in RPMI
1640 (Dutch modification; GIBCO Europe B.V., Breda, The
Netherlands), supplemented with 10% foetal calf serum
(GIBCO Limited, Paisley, Scotland), 2 mM L-glutamine,
50fgml-' streptomycin and 50 IUml-' penicillin. Exponen-
tially growing cells were harvested by trypsinisation and
5 x 105 cells in 0.05 ml Hank's Balanced Salt Solution were
subcapsularly injected into the right and left main lobe of the
liver. For the pharmacokinetic study, a third tumour was
induced in the right accessory lobe. Ten days after inocula-
tion, the mean cross sectional area (i x 0.25 x largest dia-
meter x perpendicular diameter) of the tumours was 23 ± 6
mm2 (n = 68).
Melphalan
Melphalan was kindly supplied by Wellcome Pharmaceuticals
B.V. (Utrecht, The Netherlands). One hundred mg melphalan
was first dissolved in 1.8 ml acid alcohol solvent and 9 ml
of Wellcome Deluent and subsequently diluted with sterile
saline. Solutions containing 4 mgml1' could be stored
several weeks at - 200C.
The dose-response curve of melphalan was determined for
CC531 using a monolayer colony-forming assay. Two hun-
dred and fifty cells were seeded in 6-well tissue culture plates
and after 24 h the attached cells were exposed to 0, 5, 20, 40,
70, 100 and 160ggml-' melphalan during 20 or 60 min.
Immediately after exposure plates were washed twice and
subsequently fresh medium was added. The plates were kept
in a humidified incubator for 8 days at 37°C in 5% CO2. The
plates were fixed by ethanol and the colonies were stained
with Coomassie Brilliant Blue for counting. The surviving
fraction was calculated as the number ofsurviving colonies in
treated culture divided by that in untreated (control) culture.
The concentration of melphalan at which the surviving
fraction is 0.5 is IDs.
Toxicity study
The maximally tolerated dose of melphalan for HAI was
determined by assigning non-tumour-bearing rats to: 4, 6, 8
and 12 mgkg-' melphalan. Based on the results of the
previously performed toxicity studies with 5-fluorouracil and
mitomycin C (de Brauw et al., 1989; Marinelli et al., 1990a)
the maximally tolerated dose for isolated liver perfusion was
subsequently determined by treating rats with 2, 3 and 4
times the maximally tolerated dose for HAI (12, 18 and
24mg kg-'). As a control, four rates were treated with saline
0.9% via HAI and four rats underwent ILP without drug.
Toxicity parameters
Survival, weight, white blood cell (WBC) count, and serum
levels of sodium (Na+), potassium (K+), urea, creatinine,
serum glutamic-oxaloacetic acid (SGOT), serum glutamic-
pyruvic acid (SGPT) and bilirubin (BIL) were chosen to
determine systemic and hepatic toxicity. After treatment the
rats were weighed twice a week (on days 3 and 7). Once a
week (on day 7) 1 ml blood was collected by a retro-orbital
puncture to determine the WBC count and blood chemistry.
WBC count was also determined on day 3.
Na+, K+, urea and creatinine were determined on a
Dimension (DuPont, Wilmington, DE, USA) and SGOT,
SGPT and bilirubin on a RA 1000 (Technicon, Tarrytown,
NY, USA).
The 5% and 95% limits of the normal value range were
determined on basis of 50 blood samples collected from 50
healthy rats.
Melphalan concentration study in tissue andbiofluid
Rats bearing three tumours were randomly assigned to the
following treatment groups: (1) 6 mgkg-' melphalan via
bolus HAI (n=7); (2) 6mgkg-' (n=7) and (3) 12mgkg-'
(n = 6) as bolus in the ILP circuit.
Liver biopsies of 150 to 200 mg were taken at 5, 10, 15, 20
and 25 min after bolus injection and tumour was excised at 5,
15 and 20 min (tumour weight: 70 to 150mg). From HAI
treated rats blood samples (0.5 ml) were taken at 5, 10, 15, 20
and 25 min. From ILP treated rats perfusate (0.5 ml) was
sampled at 5, 10, 15 and 20 min and blood was sampled just
after the washout (± 25 min). Blood or perfusate loss as a
result of sampling was minimal (Marinelli et al., 1990a).
Samplepretreatment
Liver and tumour tissues were homogenised in 2 ml acetoni-
trile with a Polytron (Kinematica, Luzern, Switzerland) and
immediately frozen in liquid nitrogen to stop metabolism of
melphalan. Prior to storage samples were thawed and centri-
fuged at 2,500g, an aliquot ofthe supernatant (500-1,000i1)
was dried in the vacuum centrifuge and stored at - 30°C.
Prior to analysis, samples were thawed, dissolved in the
mobile phase and injected into the HPLC system.
Plasma and perfusate samples were centrifuged for 15 min
at 800g and supernatants were stored at - 30°C. After thaw-
ing and centrifugation at 2,500g, supernatants of perfusate
were injected into the HPLC system directly, and super-
natants of plasma after deproteination by addition of 1 mol
1'1 perchloric acid, vortexing and centrifugation. All super-
natants were injected into the HPLC-system within 30 min.
Together with the samples of each rat, samples for a
calibration line were collected by spiking 200 mg liver in 2 ml
acetonitrile with a range ofmelphalan concentrations; sample
pretreatment and storage of these samples was identical toISOLATED LIVER PERFUSION WITH MELPHALAN 1071
that described above. Calibration and analysis of the 'rat'
samples was always performed on 1 day.
Recovery measurements
To determine the recovery of melphalan 2 ml mobile phase
(HPLC grade acetonitrile (25 v/v %) and 0.17 mol 1' acetic
acid (75%) with pH 2.8), 2ml plasma, 2 ml perfusate or 2 ml
acetonitrile (Chemicals Limited, Walkerburn, Scotland,
HPLC grade) were spiked with different known amounts of
melphalan. Immediately after addition-of melphalan to the
plasma and perfusate, and addition of 200 mg liver to the
acetonitrile solutions the samples were pretreated for HPLC
analysis as described above, and subsequently injected into
the HPLC system. HPLC analysis of the samples revealed
that the recovery of melphalan from plasma and perfusate,
and from the solution containing the homogenised liver was
61%, 88% and 84%, respectively.
High-performance liquidchromatography (Ahmed & Hsu,
1981; Bosanquet & Gilby, 1982)
All melphalan concentrations were measured using HPLC.
The liquid chromatograph consisted of a high pressure pump
(Spectroflow 400, Kratos, Ramsey, NJ, USA) combined with
an LC-UV variable wavelength detector (Spectroflow 773,
Kratos, Ramsey, NJ, USA). The flow rate was 0.5 ml min-',
and the UV-detector was set on 263 nm. Injection was per-
formed with an autosampler Promis II (Spark Holland,
Emmen, The Netherlands). Integration was done with a
Shimadzu C-R3A (Shimadzu, Kyoto, Japan). The analytical
column was a stainless steel tube, 100 mm x 3 mm i.d.,
packed with Nucleosil C18 (5 ,sm particles) (Macherey-Nagel,
Duren, Germany).
Antitumour effect study
Tumour bearing rats with two tumours each were randomly
assigned to five groups: (1) untreated control (n = 8), (2)
hepatic artery infusion without drug (n = 4), (3) isolated liver
perfusion without drug (n = 4), (4) hepatic artery infusion
with 6mgkg-' (n = 8) and (5) isolated liver perfusion with
12 mgkg-' (n = 10). On days 0 (day of treatment), 14, 28
and 42 rats were weighed and in order to measure liver
tumours laparotomy was performed. Cross sectional areas of
the tumours were estimated by calliper measurements and
calculated as: i x 0.25 x maximal diameter x perpendicular
diameter. Rats were sacrificed at day 42 because the tumours
in groups (1) to (4) became too large.
Statistics
For the toxicity study as well as the drug concentration study
one way analysis of variance at each time point was used to
compare the means of the different groups. If significant
differences were detected, a multiple range test, according to
Scheffe was performed. A P<0.05 was considered signifi-
cant. To compare the white blood cell count at each time
point with the starting value, a paired t-test was used for
each group (P<0.01 was considered significant). The same
test was used to compare the perfusate concentration at each
time point with the concentration at the previous time point
(P<0.05 was considered significant).
Results
Toxicity study
Time-weight change curves Figure la shows the average
changes in body weight after treatment via HAI. Treatment
with 4 mgkg-' via HAI resulted in minor weight loss com-
pared with the HAI control. As shown, after infusion of
8 mgkg-' rats continued losing weight until day 10, and the
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Figure la and b Average change in weight of wistar derived
WAG/Ola rats (weighing 260 to 360 g) treated with different
doses of melphalan a, by bolus hepatic artery infusion: x 0
(n =4), 0 4 (n =4), * 6 (n =4), + 8 (n = 5) and * 12
(n = 3) mg melphalan per kg body weight or b, by bolus admini-
stration in isolated liver perfusion: x 0 (n = 4), 0 12 (n = 4),
A 18 (n =4) and x 24 (n =4) mg melphalan per kg body
weight. I x = one death.
weight. Rats receiving 12 mgkg' via HAI died within 3
days.
In contrast, all rats treated with 12 mgkg' in ILP sur-
vived this treatment. Treatment with 18 and 24 mgkg-' was
lethal within 7 days (Figure lb).
White blood cell count All rats treated with melphalan via
HAI had a significantly decreased white blood cell count at
day 3 (P<0.01) (Figure 2). In most rats, WBC count was
still significantly decreased at day 7. Following ILP with
12mgkg'1 a minor decrease in the white blood cell count
was seen at day 3 and 7 (Figure 2). On day 14 all four rats
showed a doubling of the WBC count being normalised at
day 21. Moreover, after increasing the dose from 142 to 18
or 24 mg kg-' almost no white blood cell was left at day 3.
Blood chemistry In all HAI and ILP treated rats the serum
levels of sodium, potassium, urea, creatinine, bilirubin, serum
glutamic-oxaloacetic transaminase and serum glutamic-pyru-
vic transaminase remained within the 5% and 95% range of
the normal values during the whole follow-up period of 35
days (data not shown).
Concentrations ofmelphalan in tissue andbiofluids
The mean concentrations of melphalan in tumour and liver
tissue at various time intervals after HAI and ILP respec-
tively are presented in Figure 3a and 3b. ILP with 6 mgkg-l






Figure 2 Average WBC count ( x IO9 1-') after administration of
bolus melphalan by hepatic artery infusion: * 0 (n = 4), 0 4
(n =4), * 6 (n =4), + 8 (n = 5) and 0 12 (n = 3) mg mel-
phalan per kg body weight or by bolus administration in isolated
liver perfusion: * 12 (n = 4), A 18 (n = 4) and x 24 (n =4)
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resulted in significantly higher concentrations in tumour tis-
sue than HAI with the same dose (P<0.05) (Figure 3a). The
concentration of melphalan in tumour tissue achieved with
ILP was 3.8 times higher than the concentration 15 min after
HAI (145 ± 28 figg-' vs 38 ± 16 tLgg-'). Also in liver tissue
significant differences in mean concentrations were detected
between the various treatment groups (Figure 3b), the peak
concentration in the 12 mgkg-' in ILP group being 4.2 times
higher than in the HAI group (310 ± 102 figg-' vs 73 ± 26
gg9'). Comparing the ratio's of the mean drug concentra-
tions in liver vs tumour tissue as measured at t = 15min,
values were 1.42, 2.07 and 2.19 for HAI (6mgkg-'), ILP
(6mgkg-') and ILP (12mgkg-') respectively.
In perfusate the melphalan concentration significantly
decreased between t = 5 and 15 min (Figure 4) while in liver
and tumour tissue the melphalan concentration increased
during this time interval. At all time points the melphalan
concentration in perfusate was significantly lower than in
liver (maximally about nine times) and in tumour tissue
(maximally about five times).
In plasma maximal concentrations of 14 gml-' were
measured S min after HAI and concentrations of 1 jigml-
and 2 tgml-' after washout and re-establishment of the
normal liver circulation following ILP with 6mgkg' and
12mg kg-', respectively.
Dose-response curve ofmelphalan
The dose-response curve is shown in Figure 5. The IDo value
of CC531 for melphalan at 20min is 171igmlml and at
60 min 9jgml'l. Above 70 Lg ml-' both for 20 and 60 min
incubation, no colonies were formed.
Effect ofmelphalan on tumourgrowth
Infusion or perfusion without drug had no effect on tumour
growth: at day 42, the mean cross sectional area of the
tumours was 350 ± 59 mm2, 379 ± 57 mm2 and 356 ± 91 mm2
in the untreated control, the hepatic artery infusion and the
ILP group, respectively (Figure 6). HAI with 6mgkg- of
melphalan resulted in a significant retardation of tumour
growth, but not in complete remissions. In contrast, 90% of
the rats treated with 12mgkg-' in ILP setting had a com-
plete remission from day 14 till sacrifice. In one rat, one
tumour relapsed between day 14 and day 28, but this tumour



































Figure 3a and b Mean concentration of melphalan in a, tumour
tissue (± s.e.) and b, liver tissue with (± s.e.) at the various time












Figure 4 Mean concentration of melphalan in perfusate (± s.e.)
vs time curve in the two ILP treated groups: * 6 mg kg-' (n = 7)
and x 12mgkg-' (n=6).
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phalan treated rats, is in line with the serious hepatic toxicity
(veno-occlusive disease) (Lazarus et al., 1982) or the mild,
asymptomatic, and transient elevation of liver function tests
(Lazarus et al., 1983; Leff et al., 1986) seen in patients treated
with high dose mitomycin C or melphalan with autologous
bone marrow transplantation. In these studies, mitomycin C
was 3 to 4.5 times higher (60-90mg m2) while melphalan
was five times higher (180mgm2) than the recommended
single bolus doses i.v. without bone marrow support (Dorr &
Fritz, 1980).
A second result from our study is that the distribution of
melphalan was remarkably different from that observed in
the earlier study with mitomycin C: (1) with melphalan, ILP
resulted in significantly higher tumour and liver tissue con-
centrations than HAI with the same dose. With the two times
1U;V1kVr t-I4illhd Ular-at Ane iLn TU.PJin PGi n fV r timL
1 10 100 1000 mlgner maxlmaiiy tvLoiratu uvbs; in1 iLFr
ilH SVVC JUUF L1111b higher concentration in tumour tissue could be achieved. In
!ntration of melphalan (p.g ml- ) contrast, with mitomycin C no difference in tumour and liver
iving fraction (± s.e.) of CC531 colonies tissue concentrations administering the same dose in ILP and
)n of melphalan concentration. Exposure via HAI was seen, and with thefour times higher maximally
< 60min. Each point is the mean of three tolerated dose in ILP a four times higher concentration in
tumour tissue could be achieved; (2) the concentration of
melphalan in liver tissue was significantly higher than in
tumour tissue (ratio 1.4 to 2.2), whereas the concentration of
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lower than in tumour tissue (ratio 0.6 to 0.9); (3) in contrast
to the concentration of mitomycin C the concentration of
melphalan was significantly lower in perfusate than in
tumour and liver tissue. The uptake of melphalan by both
liver and tumour tissue is apparently much faster than the
uptake of mitomycin C. This difference may be explained by
the active transport of melphalan into the cell mediated by
two amino acid carrier systems (Begleiter et al., 1979; Gold-
enberg et al., 1979; Vistica, 1979). This active transport could
also explain the significant difference between the concentra-
tions in tissue and perfusate. Furthermore, the difference in
the concentration in tumour and liver tissue may be due to a
difference between the active transport capacity of tumour
and liver cells.
In this study, the mean (± s.e.) peak concentration of
melphalan in perfusate was 42 ± 7 Lgml- at t = 5 min in
isolated liver perfusion with 12mgkg'. This is three times
higher than the highest plasma concentration reported in
patients receiving 140 to 180mgm2 i.v. (Taha et al., 1983;
Gouyette et al., 1986), and six to ten times higher than the
maximum plasma concentrations measured in patients receiv-
ing conventional i.v. doses (0.5 to 0.6mgkg-'; 10 to 20mg
mI2l) (AllJprte W 14. Q£7Q1 Rrny se Rir5lpttIQ71Q7 RI, nnniLpt 14~ ~ ~ ~ ~~~~~~~I 28 111 J U1W L6 Ut., 1717, JD1UA OCX VIMULLL, 1717, XRV5411LIUCL 14 28 42 & Gilby, 1982; Loos et al., 1988). In contrast, 1.25 to three
Days after treatment times higher concentrations have been reported in the per-
umour cross-sectional area (mean± s.e.) fusate during isolated extremity perfusion in man (Briele et
tumours (two tumours per rat): 0 control al., 1985; Minor et al., 1985). Furthermore, the peak concen-
I without drug (n =4); O ILP without tration in the perfusate of the four patients treated with
with 6mgkg-' (n = 9); and x ILP with 0.5 mgkg-' body weight in isolated liver perfusion was 12 to
nly in the ILP group complete remissions 60jgml' (Hafstrom et al., 1990). Plasma and perfusate
en). concentrations are well within the range of plasma and
perfusate concentrations measured in patients. These concen-
trations are much higher than those achieved with i.v. admini-
stration of maximally tolerated doses in combination with
autologous bone marrow transplantation.
Different studies evaluating the antitumour effect of mel-
we found that in contrast to earlier phalan in vivo and in vitro using colony forming assays
cin C (Marinelli et al., 1990a), hepatic showed steep dose response curves (Greig et al., 1988; Bates
e limiting after ILP with melphalan. & Mackillop, 1990). In most in vitro studies tumour cell
dose limiting suggesting a significant survival was less than 0.1% after 20 min to 1 h exposure with
elphalan. relatively low concentrations of melphalan (less than
(1980) demonstrated high concentra- 20jig ml-') (Barlogie & Drewinko, 1977; Zwelling et al.,
n bile of rats. Re-absorption of the 1979; Millar et al., 1986; Bates & Mackillop, 1990), in com-
the bile therefore seems a likely ex- parison with the concentrations of melphalan needed in our
temic toxicity after ILP. This implies CC531 colony forming assay (Figure 5). In vitro, 20min
erated dose may not have been reached exposure to the melphalan concentrations measured in
postoperative bile drainage may allow tumour tissue of the rats treated with 6 mg kg' via HAI
h higher doses in ILP. Ongoing experi- (ranging from 24 to 38jigg-') resulted in 60 to 85% cell kill.
Is issue. this corresponds with the finding in vivo that although a
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significant tumour growth delay could be obtained with HAI,
this treatment did not result in complete remissions. The
concentrations of melphalan measured in tumour tissue fol-
lowing ILP with 12 mg kg-' (ranging from 88 to 145figg-)
resulted in 100% cell kill in the colony forming assay (20 min
exposure). This result is in line with the complete remissions
seen in the ILP treated rats.
ILP with mitomycin C also resulted in complete remissions
in rats (Marinelli et al., 1991). The technique ofisolated liver
perfusion has been already extensively and successfully tested
in patients by different groups (Aigner et al., 1988; Skibba et
al., 1988; Hafstr6m et al., 1990) without serious (post-)
operative complications. The best clinical results (however
still preliminary, phase I/II) were obtained administering
mitomycin C (Aigner et al., 1988). In 1990 we started a phase
I/IT trial with mitomycin C in ILP. No serious operative
morbidity was encountered, mean hospitalisation was less
than 2 weeks and objective responses were seen in six out of
seven evaluable patients (manuscripts in preparation). Unfor-
tunately, ILP with mitomycin C was associated with hepato-
toxic side effects in man as in rats (Marinelli et al., 1990a).
In conclusion, this study demonstrates that with ILP high-
ly effective concentrations of melphalan can be achieved in
tumour tissue in a dose range for which hepatic toxicity is
negligible. These results suggest that melphalan is preferable
to mitomycin C in the high dose chemotherapeutic treatment
of liver metastases in ILP setting. Whether the results with
melphalan are even more favourable if the same dose is
administered as a 25 min continuous infusion instead of as a
bolus in the hepatic artery will be investigated. This will be
studied in HAI as well as in ILP setting. Furthermore, a
clinical phase I/TI study of isolated liver perfusion will be
started with melphalan.
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